← Back to headlines
Gilead Sciences to Acquire Ouro Medicines for T-Cell Therapy Boost
Gilead Sciences is set to acquire biotech firm Ouro Medicines in a deal valued at over $2 billion, aiming to boost its T cell therapy capabilities for autoimmune diseases.
23 Mar, 22:28 — 24 Mar, 05:55
The Story
Analyzing sources…
Source Diversity
Source Diversity
Moderate (32/100)2 sources— more sources would strengthen this score15/33
Spectrum spread— 2/5 buckets covered8/33
Far L
Left
Center1
Center (1)
Reuters
Right1
Right (1)
seeking-alpha
Far R
Geographic diversity— 2 regions9/34
US1Intl1
ℹOnly 2 sources cover this story
Sources
Showing 2 of 2 sources
ReutersVery High9h ago
Gilead to buy biotech firm Ouro Medicines in over $2 billion deal - Reuters
Gilead to buy biotech firm Ouro Medicines in over $2 billion deal Reuters
Read full article →seeking-alphaMixed1h ago
Gilead Sciences to buy Ouro Medicines to boost T cell therapy for autoimmune diseases
Read full article →Coverage Timeline
First report: Reuters · 23 Mar, 22:28|Full coverage: 2 · 7h|Window: 7h
Left-leaningCenterRight-leaning
Related Stories
Jury Deadlocks in Landmark US Social Media Addiction Trial Against Google and Meta
just now
Amazon Confirms AWS Bahrain Region Disrupted by Drone Activity
just now
Apple to Host WWDC on June 8, Expected to Announce AI Comeback and Maps Ads
7m ago
China Approves World's First Brain Implant for Paralysis
9m ago